denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Integrating New Therapies into the Management of Classical Heme Disorders
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Drug development, Clinical Research, Thalassemia, Education, Hemoglobinopathies, Pediatric, Diseases, Real-world evidence, Treatment Considerations, Adverse Events, Young adult , Study Population, Human
Session: Integrating New Therapies into the Management of Classical Heme Disorders
Hematology Disease Topics & Pathways:
Research, Clinical trials, Adult, Clinical Practice (Health Services and Quality), Drug development, Clinical Research, Thalassemia, Education, Hemoglobinopathies, Pediatric, Diseases, Real-world evidence, Treatment Considerations, Adverse Events, Young adult , Study Population, Human
Saturday, December 7, 2024, 2:00 PM-3:15 PM
Disclosures: Fertrin: Sanofi Genzyme: Consultancy; Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bluebird bio: Membership on an entity's Board of Directors or advisory committees. Taher: Vifor: Consultancy, Research Funding; Pharmacosmos: Consultancy, Research Funding; Novo Nordisk: Consultancy; Bristol Myers Squibb (Celgene): Consultancy, Research Funding; Agios Pharmaceuticals, Inc.: Consultancy, Research Funding.
OffLabel Disclosure: I will discuss off-label use of luspatercept in non-transfusion dependent thalassemias.
See more of: Integrating New Therapies into the Management of Classical Heme Disorders
See more of: Education Program
See more of: Education Program